ArticleBMC cancer2024
Clinicopathological characteristics, treatment patterns and outcomes in patients with HER2-positive breast cancer based on hormone receptor status: a retrospective study.
Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Optimizing the ER Cutoff in HER2-Positive Breast Cancer: ER ≥ 50% Predicts Low pCR Rates and Resistance to Antibody-Drug Conjugates in the Neoadjuvant Setting.Cancer medicine · 2026Article
- Comparison of Neoadjuvant TCHP and ddAC+THP Regimens for Pathologic Complete Response in HER2-Positive Breast Cancer: A Multicenter Real-World Analysis of Systemic Inflammatory Biomarkers.Medicina (Kaunas, Lithuania) · 2026Article
- Impact of High Lymph Node Burden on Brain Metastases in Patients Who Achieved Pathological Complete Response after Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.Cancer research and treatment · 2026Article
- MRI quantification of intratumoral heterogeneity for predicting HER2-positive status in breast cancer: a retrospective multicenter study.BMC cancer · 2026Article
- Role of laser therapy in enhancing chemotherapy efficiency in breast cancer: low level laser therapy, photochemotherapy, and photodynamic therapy as promising treatments.Lasers in medical science · 2026Review
- Predictive Role of Pre-Radiotherapy D-Dimer and Inflammatory Markers in Monitoring Outcomes After Treatment in Hormone-Positive Breast Cancer: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- HER2 Overexpression in Invasive Breast Carcinoma in the Democratic Republic of Congo and its Association with Selected Clinicopathological Characteristics.Breast cancer (Dove Medical Press) · 2026Article
- Postoperative radiotherapy improves long-term survival in HER2-positive metastatic breast cancer: real-world evidence from the latest SEER database.Breast cancer research and treatment · 2025Article
- HER2-Positive Breast Cancer-Current Treatment Management and New Therapeutic Methods for Brain Metastasis.Biomedicines · 2025Review
- Letter Re: Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world.ESMO open · 2025Article
- Histopathological and Clinical Features of HER2-Positive Breast Cancers across Hormone Receptor Subgroups: A Cross-Sectional Analysis.F1000Research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundDifferent hormone receptor (HR) expression patterns have significant biological and therapeutic implications in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, the distinction between HR-positive /HER2-positive (HR+/HER2+) and HR-negative/HER2-positive (HR-/HER2+) subtypes remains unclear.
methodsThis retrospective study analyzed 828 patients with HER2-positive breast cancer at the First Affiliated Hospital of Xi'an Jiaotong University from 2012 to 2022. Baseline characteristics were compared by chi-square test. Survival outcomes were estimated by Kaplan-Meier method.
resultsIn total, 56.3% (n = 466) had HR-positive and 43.7% (n = 362) had HR-negative disease. Comparatively, HR+/HER2 + breast cancers presented favorable clinicopathological features. At a median follow-up of 49 months, 199 disease-free survival (DFS) events and 99 deaths were observed. HR+/HER2 + patients had significantly better survival outcomes than HR-/HER2 + patients. HR-positive status was an independent protective factor for overall survival (OS) [P = 0.032; hazard ratio, 0.61; 95% confidence interval (CI), 0.39-0.96] and DFS (P = 0.001; hazard ratio, 0.61; 95% CI, 0.46-0.81). HR+/HER2 + patients were significantly less sensitive to neoadjuvant therapy than HR-/HER2 + patients. In the first-line treatment for HR+/HER2 + advanced breast cancer, receiving endocrine therapy significantly improved advanced-OS (P < 0.001; hazard ratio, 0.33; 95% CI, 0.18-0.59) and progression-free survival (PFS) (P < 0.001; hazard ratio, 0.38; 95% CI, 0.25-0.58) compared with not receiving endocrine therapy. Moreover, maintenance endocrine therapy after HER2-targeted therapy and chemotherapy is associated with significant advanced-OS and PFS benefits compared with no maintenance endocrine therapy (advanced-OS: P < 0.001; hazard ratio, 0.05; 95% CI, 0.03-0.12; PFS: P < 0.001; hazard ratio, 0.35; 95% CI, 0.21-0.57).
conclusionsThis study reveals the high heterogeneity of HER2-positive breast cancer related to HR status in clinicopathological features, metastasis patterns, and outcomes. Large randomized controlled trials are warranted to optimize treatment strategies for the HER2-positive breast cancer population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.